References
- N Engl J Med v.341 Behcet's disease. Sakane T;Takeno M;Suzuki N;Inaba G
- Semin, Arthritis Rheum v.27 Behcet's disease. Kaklamani VG;Vaiopoulos G;Kaklamanis PG.
- Seminars in Arthritis and Rheumatism. v.8 Behcet Disease. Shimizu, T.;Ehrlich, G.E.; Inaba, G.(et, al)
- 금괘요략講義 何任(主編)
- 增補萬病回春(下卷) 襲廷賢
- 中國醫學史 洪元植
- 漢方臨床알레르기 康秉秀
- 增補最新漢方臨床學 裵元植
- Isr J Med Sci v.31 Elevated serum interleukin 1 receptors and interleukin 1b in patients with Behcet's disease: Correlations with disease activity and severity. Yosipovitch G;Shohat B;Bshara J;Wysenbeek A;Weinberger A.
- J Rheumatol v.20 Overproduction of monocyte derived tumor necrosis factor , interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet's disease. A comparative study with familial Mediterranean fever and healthy subjects. Mege JL;Dilsen N;Sanguedolce V;Gul A;Bongrand P;Roux H(et al.)
- J Rheumatol v.23 Cytokines in Behcet's disease. Sayinalp N;zcebe OI;zdemir O;Haznedaro lu IC;Dundar S, Kirazli
- Arthritis and allied conditions: a textbook of rheumatology. v.1 Intermittent and periodic arthritic syndromes. Kastner DL.;Koopman WJ(Ed.)
- 臨床皮膚科 雜誌 v.26 no.3 中西醫結合治療白塞病療效觀察 吳之伍(外)
- 巢氏諸病源候論 巢元方
- 이화의대지 v.6 no.4 Behcet씨 證候群의 臨床的 硏究 김종남
- Br. J. Dermatol. v.95 Histological and direct immunofluorescence study of cutaneous hyperreactivity in Behcet disease. Haim S;Sobel JD;Friedman-Birnbaum R; Lichtig C
- 方藥合編解說 申載鏞
- 醫學入門 v.4;6 이천
- 原本東醫寶鑑 許浚
- 臨床本草學 辛民敎
- 國譯景岳全書(上) v.6 張介賓
- J Am Acad Dermatol v.19 Behcet's disease. New perspectives on an enigmatic syndrome. Arbesfeld SJ;Kurban AK.
- 診療要覽 金定濟
- Int J Clin Pract v.55 Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (Remicade). Bondeson J;Maini RN.
- Arthritis Rheum v.44 The combination of tumor necrosis factor- blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Chabaud M;Miossec P.
- 增補韓方臨床40年 朴炳坤
- Gastroenterology v.120 Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: Case report. Hassard PV;Binder SW;Nelson V;Vasiliauskas EA.
- Am J Med v.108 Thalidomide: Current and potential clinical applications. Calabrese L;Fleischer AB.
- J Exp Med v.173 Thalidomide selectively inhibits tumor necrosis factor production by stimulated human monocytes. Sampaio EP;Sarno EN;Galilly R;Cohn ZA;Kaplan G.
- Clin Exp Immunol v.99 The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral mononuclear cell cultures. McHugh SM;Rifkin IR;Deighton J;Wilson AB;Lachmann PJ;Lockwood CM(et al.)
- 原本編註醫學入門(下) v.3 이천
- Br J Ophthalmol v.76 Low dose cyclosporin A versus plused cyclophosphamide in Behcet's syndrom: a single masked trial. Ozyazgan Y;Yurdakul S;Yazici H;Tuzun B;Iscimen A;Tuzun Y(et al.)
- Ophthalmology v.106 Central nervous system symptoms in patients with Behcet disease receiving cyclosporin therapy. Kotake S;Higashi K;Yoshikawa K;Sasamoto Y;Okamoto T;Matsuda H.